Twenty three percent patients dose schedule once every
Twenty-three percent of patients on a dose schedule of once every three weeks saw substantial shrinkage in their tumors, and 38 percent saw a marked reduction in the ovarian cancer biomarker CA-125.
The overall clinical benefit rate of 48 percent included patients whose disease did not progress while on two different dose regimens in the study.
The results from the study of 68 patients were presented at a meeting of the American Society of Clinical Oncology in Chicago.
These results demonstrate that NKTR-102 holds great therapeutic potential for women battling ovarian cancer, said Dr. Ignace Vergote, head of obstetrics and gynecology and gynecologic oncology at the Catholic University of Leuven, Belgium, and the studys lead investigator.
About 230,000 women worldwide are diagnosed with ovarian cancer each year, and nearly 70 percent with advanced disease die within five years.
NKTR-102 is also being tested in two separate Phase 2 clinical trials in patients with metastatic breast cancer and colorectal cancer.
Reporting by Susan Kelly in Chicago Editing by Peter Cooney source